Head to Head Contrast: HedgePath Pharmaceuticals (HPPI) versus Exelixis (EXEL)

HedgePath Pharmaceuticals (OTCMKTS:HPPI) and Exelixis (NASDAQ:EXEL) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, earnings, risk, dividends and valuation.

Valuation & Earnings

This table compares HedgePath Pharmaceuticals and Exelixis’ top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
HedgePath Pharmaceuticals N/A N/A -$5.10 million N/A N/A
Exelixis $452.48 million 11.47 $154.22 million $0.51 34.14

Exelixis has higher revenue and earnings than HedgePath Pharmaceuticals.

Volatility and Risk

HedgePath Pharmaceuticals has a beta of -5.18, suggesting that its share price is 618% less volatile than the S&P 500. Comparatively, Exelixis has a beta of 2.29, suggesting that its share price is 129% more volatile than the S&P 500.

Institutional and Insider Ownership

80.9% of Exelixis shares are held by institutional investors. 4.3% of HedgePath Pharmaceuticals shares are held by company insiders. Comparatively, 4.8% of Exelixis shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for HedgePath Pharmaceuticals and Exelixis, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
HedgePath Pharmaceuticals 0 0 0 0 N/A
Exelixis 1 2 8 0 2.64

Exelixis has a consensus target price of $30.38, indicating a potential upside of 74.47%. Given Exelixis’ higher probable upside, analysts clearly believe Exelixis is more favorable than HedgePath Pharmaceuticals.

Profitability

This table compares HedgePath Pharmaceuticals and Exelixis’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
HedgePath Pharmaceuticals N/A -1,322.60% -279.15%
Exelixis 48.17% 65.68% 43.81%

Summary

Exelixis beats HedgePath Pharmaceuticals on 10 of the 10 factors compared between the two stocks.

HedgePath Pharmaceuticals Company Profile

HedgePath Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for patients with cancers in the United States. It primarily focuses on the development of therapies for skin, lung, and prostate cancers. The company's Hedgehog signaling pathway is a primary regulator of cellular processes in vertebrates, including stem cell maintenance, cell differentiation, tissue polarity, and cell proliferation. It is conducting an open-label Phase II (b) clinical trial for studying the effect of SUBA-Itraconazole oral capsules in patients with basal cell carcinoma nevus syndrome. SUBA-Itraconazole is a patented and proprietary itraconazole formulation that enhances the absorption of itraconazole to enhance the bioavailability of orally administered drugs that are poorly soluble. The company was founded in 1992 and is headquartered in Tampa, Florida.

Exelixis Company Profile

Exelixis, Inc., a biotechnology company, engages in the discovery, development, and commercialization of new medicines to enhance care and outcomes for people with cancer. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of patients with progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. It also offers COTELLIC tablets, an inhibitor of MEK in combination with vemurafenib for the treatment of patients with BRAF V600E or V600K mutation-positive advanced melanoma in the United States; and in combination with vemurafenib in other territories, including the European Union, Switzerland, Canada, Australia, and Brazil. Exelixis, Inc. has collaboration and license agreement with Ipsen Pharma SAS, Genentech, Inc., GlaxoSmithKline, Bristol-Myers Squibb Company, Sanofi, Merck, Daiichi Sankyo Company Limited, and Invenra, Inc. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was founded in 1994 and is headquartered in South San Francisco, California.

Receive News & Ratings for HedgePath Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HedgePath Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply